PharmGKB summary: very important pharmacogene information for RYR1

被引:10
作者
Alvarellos, Maria L. [1 ]
Krauss, Ronald M. [3 ,4 ]
Wilke, Russell A. [5 ,6 ]
Altman, Russ B. [1 ,2 ]
Klein, Teri E. [1 ]
机构
[1] Stanford Univ, Dept Genet, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA
[3] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA
[4] UCSF, Oakland, CA USA
[5] Univ N Dakota, Dept Med, Fargo, ND USA
[6] Sanford Healthcare, IMAGENET, Sioux Falls, SD USA
关键词
CENTRAL CORE DISEASE; MALIGNANT HYPERTHERMIA MUTATION; MUSCLE SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR MUTATIONS; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; GENETIC RISK; MYOTUBES; CA2+; 4-CHLORO-M-CRESOL;
D O I
10.1097/FPC.0000000000000198
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
[No abstract available]
引用
收藏
页码:138 / 144
页数:7
相关论文
共 87 条
  • [1] Phenotype Standardization for Statin-Induced Myotoxicity
    Alfirevic, A.
    Neely, D.
    Armitage, J.
    Chinoy, H.
    Cooper, R. G.
    Laaksonen, R.
    Carr, D. F.
    Bloch, K. M.
    Fahy, J.
    Hanson, A.
    Yue, Q-Y
    Wadelius, M.
    Maitland-van der Zee, A. H.
    Voora, D.
    Psaty, B. M.
    Palmer, C. N. A.
    Pirmohamed, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (04) : 470 - 476
  • [2] Noninvasive testing for malignant hyperthermia susceptibility
    Allen, PD
    López, JR
    [J]. ANESTHESIOLOGY, 2002, 97 (05) : 1045 - 1046
  • [3] An integrated map of genetic variation from 1,092 human genomes
    Altshuler, David M.
    Durbin, Richard M.
    Abecasis, Goncalo R.
    Bentley, David R.
    Chakravarti, Aravinda
    Clark, Andrew G.
    Donnelly, Peter
    Eichler, Evan E.
    Flicek, Paul
    Gabriel, Stacey B.
    Gibbs, Richard A.
    Green, Eric D.
    Hurles, Matthew E.
    Knoppers, Bartha M.
    Korbel, Jan O.
    Lander, Eric S.
    Lee, Charles
    Lehrach, Hans
    Mardis, Elaine R.
    Marth, Gabor T.
    McVean, Gil A.
    Nickerson, Deborah A.
    Schmidt, Jeanette P.
    Sherry, Stephen T.
    Wang, Jun
    Wilson, Richard K.
    Gibbs, Richard A.
    Dinh, Huyen
    Kovar, Christie
    Lee, Sandra
    Lewis, Lora
    Muzny, Donna
    Reid, Jeff
    Wang, Min
    Wang, Jun
    Fang, Xiaodong
    Guo, Xiaosen
    Jian, Min
    Jiang, Hui
    Jin, Xin
    Li, Guoqing
    Li, Jingxiang
    Li, Yingrui
    Li, Zhuo
    Liu, Xiao
    Lu, Yao
    Ma, Xuedi
    Su, Zhe
    Tai, Shuaishuai
    Tang, Meifang
    [J]. NATURE, 2012, 491 (7422) : 56 - 65
  • [4] PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics
    Alvarellos, Maria L.
    McDonagh, Ellen M.
    Patel, Sephalie
    McLeod, Howard L.
    Altman, Russ B.
    Klein, Teri E.
    [J]. PHARMACOGENETICS AND GENOMICS, 2015, 25 (12) : 622 - 630
  • [5] Ryanodine receptor calcium release channels: lessons from structure-function studies
    Amador, Fernando J.
    Stathopulos, Peter B.
    Enomoto, Masahiro
    Ikura, Mitsuhiko
    [J]. FEBS JOURNAL, 2013, 280 (21) : 5456 - 5470
  • [6] [Anonymous], DAT SINGL NUCL POL D
  • [7] Appiah-Ankam J., 2004, CONTIN ED ANAESTH CR, V4, P2, DOI [DOI 10.1093/BJACEACCP/MKH002, 10.1093/bjaceaccp/mkh002]
  • [8] Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor
    Avila, G
    Dirksen, RT
    [J]. JOURNAL OF GENERAL PHYSIOLOGY, 2001, 118 (03) : 277 - 290
  • [9] Dantrolene-Induced Inhibition of Skeletal L-Type Ca2+ Current Requires RyR1 Expression
    Bannister, R. A.
    [J]. BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [10] Contractile impairment and structural alterations of skeletal muscles from knockout mice lacking type 1 and type 3 ryanodine receptors
    Barone, V
    Bertocchini, F
    Bottinelli, R
    Protasi, F
    Allen, PD
    Armstrong, CF
    Reggiani, C
    Sorrentino, V
    [J]. FEBS LETTERS, 1998, 422 (02): : 160 - 164